Search For "covaxin"
Covaxin safe for children aged 2-18 years, says Bharat Biotech
Updated : 1 week, 5 days ago IST
Hyderabad (Telangana) [India], June 17 (ANI): Bharat Biotech International Limited (BBIL) on Thursday announced that Covaxin, its whole-virion inactivated COVID-19 vaccine has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study, said a press
Read More
Covaxin booster shot enhances efficacy against Delta, Omicron variants of
Updated : 2 weeks ago IST
New Delhi [India], June 15 (ANI): A study showed that administration of Covaxin booster dose will enhance the vaccine effectiveness against the Delta variant infection and give protection against two Omicron variants of COVID-19.
Read More
DCGI approves Corbevax as first heterologous COVID-19 booster shot for adu
Updated : 3 weeks, 4 days ago IST
Hyderabad (Telangana) [India], June 4 (ANI): Biological E. Limited, a Hyderabad-based pharmaceutical and vaccines company, on Saturday, announced that its Corbevax COVID-19 vaccine has been approved by the Drug Controller General of India (DCGI) as a heterologous COVID-19 booster dose for
Read More
Germany to recognize Bharat Biotech's COVAXIN for travel from June 1
Updated : 1 month ago IST
New Delhi [India], May 26 (ANI): German Ambassador to India, Walter J Lindner, on Thursday hailed the German government for recognizing the WHO-listed Bharat Biotech's COVID vaccine, COVAXIN, for travel to the country starting June 1.
Read More
FDA removes hold on clinical trial for phase 2,3 for COVAXIN-BBV152 says
Updated : 1 month ago IST
Malvern (Pennsylvania) [US], May 23 (ANI): Biotechnology company Ocugen on Monday announced that the US Food and Drug Administration (FDA) lifted the clinical hold on the Company's Phase 2, 3 clinical trials for COVAXIN™ (BBV152).
Read More
Bharat Biotech seeks DCGI's permission to conduct Covaxin booster trials i
Updated : 1 month, 3 weeks ago IST
New Delhi [India], May 4 (ANI): Hyderabad-based pharma company Bharat Biotech has sought permission from the Drugs Controller General of India (DCGI) to conduct trials of Covaxin as COVID-19 vaccine booster dose in the 2-18 age group, sources said.
Read More
'Portrays incorrect picture', MEA on reports of it asking Bharat Biotech t
Updated : 2 months ago IST
New Delhi [India], April 29 (ANI): The Minstry of External Affairs has said that media reports purportedly quoting a communication from the ministry asking vaccine maker Bharat Biotech to address issues to avoid cancellation of WHO's emergency use approval (EUA) nod for its COVID jab, "potra
Read More
India's expanding COVID-19 vaccination programme set to achieve new milest
Updated : 2 months ago IST
New Delhi [India], April 27 (ANI): India has vaccinated over 96 per cent of its adult population with at least one dose of the COVID-19 vaccine and about 84 per cent of people above 15 years of age have received both the doses.
Read More
Paediatricians welcome COVID vaccines for kids, say parents mustn't hesita
Updated : 2 months ago IST
New Delhi [India], April 26 (ANI): The Drugs Controller General of India (DCGI) on Tuesday granted an emergency use authorisation (EUA) to Bharat Biotech's Covaxin for the age group of 6-12 years.
Read More
DCGI approves COVID-19 vaccine Covaxin for children aged 6-12
Updated : 2 months ago IST
Hyderabad (Telangana) [India], April 26 (ANI): The Drugs Controller General of India (DCGI) on Tuesday granted an emergency use authorisation (EUA) to Bharat Biotech's Covaxin for the age group of 6-12 years.
Read More
DCGI gives emergency use authorisation to Covaxin for 6-12 age group
Updated : 2 months ago IST
New Delhi [India], April 26 (ANI): The Drugs Controller General of India (DCGI) gives restricted emergency use authorisation to Covaxin for the 6-12 age group.
Read More
Bharat Biotech asked to provide more data on COVID-19 vaccine Covaxin for
Updated : 2 months, 1 week ago IST
New Delhi [India], April 22 (ANI): The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its COVID-19 vaccine, Covaxin, for administering it to children aged between 2-12 years, sources said.
Read More
